In October 2008, Brainsway obtained CE Mark certification to market Deep TMS for the treatment of manic depression (bipolar disorder) in the EU following the success of a clinical trial for this indication.
Brainsway is currently conducting a number of clinical trials in parallel to test the effectiveness of Deep TMS for treating several diseases. In April, it announced a trial of the device to treat cocaine addition with the US National Institute on Drug Abuse, a unit of the National Institutes of Health.
Yesterday, the company announced preliminary good interim results for Deep TMS for the treatment of Parkinson's disease conducted at Sheba Medical Center Tel Hashomer, in Israel.
Brainsway's share rose 7% by mid-afternoon to NIS 10.90, giving a market cap of NIS 394.5 million.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments